LOUIS SILVERSTEIN: Open Payments
NPI 1033103775 · HAVRE DE GRACE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,031 in 31 payments from 12 companies in 2025. Trend: 2023 $843 · 2024 $780 · 2025 $1,031
Food & beverage: $1,031
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $279 |
| ABBVIE INC. | 12 | $208 |
| Novo Nordisk Inc | 2 | $170 |
| Otsuka America Pharmaceutical, Inc. | 1 | $111 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $73 |
| PFIZER INC. | 2 | $43 |
| Exact Sciences Corporation | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Merck Sharp & Dohme LLC | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $18 |
Products named: AIRSUPRA, REXULTI, BREZTRI, Wegovy, QULIPTA, Ozempic, UBRELVY, CAPLYTA.
Industry payments across MD — which companies pay providers there.
